Document:

Exhibit
4.63

 

COMMON
STOCK PURCHASE AGREEMENT

 

This
Common Stock Purchase Agreement (this “Agreement”) is made and entered into as of April __, 2020, by and among
Aegea Biotechnologies, Inc., a Delaware corporation (the “Company”), and Tauriga Sciences, Inc., a Delaware
corporation (“Investor”).

 

Whereas,
the Company desires to sell to the Investor, and the Investor desires to purchase from the Company, shares of the Company’s
Common Stock on the terms and conditions set forth in this Agreement;

 

Now,
therefore, the parties hereby agree as follows:

 

1. AGREEMENT
TO PURCHASE AND SELL STOCK.

 

1.1
Agreement to Purchase and Sell. The Company agrees to sell to the Investor at the Closing, and each Investor agrees
to purchase from the Company at the Closing, the number of shares of Common Stock set forth on the Stock Purchase Schedule attached
as Exhibit C to this Agreement (the “Stock Purchase Schedule”), at a price of Four Dollars ($4.00) per share,
for a total purchase price for Investor as shown on the Stock Purchase Schedule (the “Purchase Price”).
Such shares may be purchased by payment by check or wire transfer to a bank account designated by the Company. The shares of Common
Stock purchased and sold pursuant to this Agreement will be hereinafter referred to as the “Purchased Shares”.

 

2. CLOSING.

 

The
purchase and sale of the Purchased Shares will take place at the offices of Procopio, Cory, Hargreaves & Savitch LLP (“Procopio”),
upon the satisfaction or waiver of all of the conditions to closing set forth in Sections 5 herein (which time and place are hereafter
referred to in this Agreement as the “Closing”), at such time that the parties may agree. At the Closing, or
promptly thereafter, the Investors shall deliver to the Company, the Purchase Price and upon the satisfaction of the conditions
to Closing described herein, the Company will deliver to each Investor a certificate representing the number of Purchased Shares
that such Investor has agreed to purchase hereunder against delivery to the Company the full purchase price of such Purchased
Shares, paid by (i) a check payable to the Company’s order, (ii) wire transfer of funds to the Company, or (iii) any combination
of the foregoing.

 

3. REPRESENTATIONS
AND WARRANTIES OF THE COMPANY.

 

The
Company hereby represents and warrants to the Investor that the statements in the following paragraphs of this Section 3 are all
true and correct on and as of the date of this Agreement:

 

3.1 Organization,
Good Standing and Qualification. The Company has been duly incorporated and organized, and is validly existing in good
standing, under the laws of the State of Delaware. The Company has the corporate power and authority to enter into and perform
this Agreement, to own and operate its properties and assets, and to carry on its business as currently conducted and as presently
proposed to be conducted.

 

    	 

     

    

 

3.2 Due
Authorization. All corporate action on the part of the Company’s directors and stockholders necessary for the authorization,
execution, delivery of, and the performance of all obligations of the Company under this Agreement, the authorization, issuance,
reservation for issuance and delivery of all of the Purchased Shares being sold under this Agreement, will by the Closing have
been taken, and this Agreement constitutes valid and legally binding obligations of the Company, enforceable in accordance with
their respective terms, except as may be limited by (i) applicable bankruptcy, insolvency, reorganization or others laws of general
application relating to or affecting the enforcement of creditors’ rights generally and (ii) the effect of rules of law
governing the availability of equitable remedies.

 

3.3 Valid
Issuance of Stock. The Purchased Shares, when issued and paid for as provided in this Agreement will be duly authorized
and validly issued, fully paid and nonassessable.

 

3.4 Litigation.
There is no action, suit, proceeding, claim, arbitration or investigation (“Action”) pending (or, to the Company’s
knowledge, currently threatened) against the Company, its activities, properties or assets.

 

3.5 Status
of Proprietary Assets. To the Company’s knowledge, the Company has full title and ownership of, or is duly licensed
under or otherwise authorized to use, all patents, patent applications, trademarks, service marks, trade names, copyrights, mask
works, trade secrets, confidential and proprietary information, designs and proprietary rights (all of the foregoing collectively
hereinafter referred to as the “Proprietary Assets”), necessary to enable it to carry on its business as now conducted.

 

3.6 Compliance
with Law and Documents. The Company is not in violation or default of any provisions of its Certificate of Incorporation
attached hereto as Exhibit A (“Certificate of Incorporation”) or its Bylaws, attached hereto as Exhibit
B, and to the Company’s knowledge, except for any violations that individually and in the aggregate would have no material
adverse impact on the Company’s business, the Company is in compliance with all applicable statutes, laws, and regulations
of the United States of America.

 

4. REPRESENTATIONS
AND WARRANTIES OF INVESTOR.

 

The
Investor hereby represents and warrants to, and agrees with, the Company, as of the date of this Agreement that:

 

4.1 Authorization.
This Agreement constitutes such Investor’s valid and legally binding obligation, enforceable in accordance with its terms
except as may be limited by (i) applicable bankruptcy, insolvency, reorganization or other laws of general application relating
to or affecting the enforcement of creditors’ rights generally and (ii) the effect of rules of law governing the availability
of equitable remedies. Each Investor represents that such Investor has full power and authority to enter into this Agreement.

 

4.2 Purchase
for Own Account. The Purchased Shares to be purchased by such Investor hereunder will be acquired for investment for such
Investor’s own account, not as a nominee or agent, and not with a view to the public resale or distribution thereof within
the meaning of the 1933 Act, and such Investor has no present intention of selling, granting any participation in, or otherwise
distributing the same. If not an individual, such Investor also represents that such Investor has not been formed for the specific
purpose of acquiring Purchased Shares.

 

    	 

     

    

 

4.3 Disclosure
of Information. Such Investor has received or has had full access to all the information he/she/it considers necessary
or appropriate to make an informed investment decision with respect to the Purchased Shares to be purchased by such Investor under
this Agreement. Such Investor further has had an opportunity to ask questions and receive answers from the Company regarding the
terms and conditions of the offering of the Purchased Shares and to obtain additional information (to the extent the Company possessed
such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to
such Investor or to which such Investor had access. The foregoing, however, does not in any way limit or modify the representations
and warranties made by the Company in Section 3.

 

4.4 Investment
Experience. Such Investor understands that the purchase of the Purchased Shares involves substantial risk. Such Investor:
(i) has experience as an investor in securities of companies in the development stage and acknowledges that such Investor is able
to fend for itself, can bear the economic risk of such Investor’s investment in the Purchased Shares and has such knowledge
and experience in financial or business matters that such Investor is capable of evaluating the merits and risks of this investment
in the Purchased Shares and protecting its own interests in connection with this investment and/or (ii) has a preexisting personal
or business relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration
that enables such Investor to be aware of the character, business acumen and financial circumstances of such persons.

 

4.5
Accredited Investor Status. Investor is an “accredited investor” within the meaning of Regulation D promulgated
under the 1933 Act or is a non U.S. person under the 1933 Act.

 

4.6 Restricted
Securities. Such Investor understands that the Purchased Shares are characterized as “restricted securities”
under the 1933 Act inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that
under the 1933 Act and applicable regulations thereunder such securities may be resold without registration under the 1933 Act
only in certain limited circumstances. In this connection, such Investor represents that such Investor is familiar with Rule 144
of the U.S. Securities and Exchange Commission (the “SEC”), as presently in effect, and understands the resale
limitations imposed thereby and by the 1933 Act. Such Investor understands that the Company is under no obligation to register
any of the securities sold hereunder except as provided herein. Such Investor understands that no public market now exists for
any of the Purchased Shares and that it is uncertain whether a public market will ever exist for the Purchased Shares.

 

4.7 Further
Limitations on Disposition. Without in any way limiting the representations set forth above, such Investor further agrees
not to make any disposition of all or any portion of the Purchased Shares unless and until:

 

(a) there
is then in effect a registration statement under the 1933 Act covering such proposed disposition and such disposition is made
in accordance with such registration statement; or

 

    	 

     

    

 

(b) such
Investor shall have notified the Company of the proposed disposition and shall have furnished the Company with a statement of
the circumstances surrounding the proposed disposition, and, at the expense of such Investor or its transferee, with an opinion
of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such securities under
the 1933 Act.

 

Notwithstanding
the provisions of paragraphs (a) and (b) above, no such registration statement or opinion of counsel shall be required: (i) for
any transfer of any Purchased Shares in compliance with SEC Rule 144 or Rule 144A, or (ii) for any transfer of Purchased Shares
by an Investor that is a partnership or a corporation to (A) a partner of such partnership or stockholder of such corporation,
(B) a retired partner of such partnership who retires after the date hereof, (C) the estate of any such partner or stockholder,
or (iii) for the transfer by gift, will or intestate succession by any Investor to his or her spouse or lineal descendants or
ancestors or any trust for any of the foregoing; provided that in each of the foregoing cases the transferee agrees in writing
to be subject to the terms of this Section 4 (other than Section 4.5) to the same extent as if the transferee were an original
Investor hereunder.

 

4.8 Legends.
It is understood that the certificates evidencing the Purchased Shares will bear the legend set forth below:

 

THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR
UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY
NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION
OR EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO
THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES
LAWS.

 

The
legend set forth in (a) above shall be removed by the Company from any certificate evidencing Purchased Shares upon delivery to
the Company of an opinion by counsel, reasonably satisfactory to the Company, that a registration statement under the 1933 Act
is at that time in effect with respect to the legended security or that such security can be freely transferred in a public sale
without such a registration statement being in effect and that such transfer will not jeopardize the exemption or exemptions from
registration pursuant to which the Company issued the Purchased Shares.

 

    	 

     

    

 

4.9
Lock-Up Agreement. The Investor agrees that it will not, without the prior written consent of the managing underwriter
in an initial Company IPO, (1) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase
any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly
or indirectly, any of the Purchased Shares, or (2) enter into any swap or other arrangement that transfers to another, in whole
or in part, any of the economic consequences of ownership of such Purchased Shares, during the one hundred eighty (180) day period
following the effective date of the registration statement for the Company’s IPO (as defined below) (or such other period
as may be requested by the Company or an underwriter, and agreed to by all other stockholders of the Company, to accommodate regulatory
restrictions on (a) the publication or other distribution of research reports and (b) analyst recommendations and opinions, including,
but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or
amendments thereto.

 

5. CONDITIONS
TO INVESTOR’S OBLIGATIONS AT CLOSING.

 

The
obligations of Investor under Section 2 of this Agreement are subject to the fulfillment or waiver, on or before the Closing,
of each of the following conditions, the waiver of which shall not be effective against any Investor who does not consent to such
waiver, which consent may be given by written, oral or telephone communication:

 

5.1 Representations
and Warranties True. Each of the representations and warranties of the Company contained in Section 3 shall be true and
correct on and as of the Closing with the same effect as though such representations and warranties had been made on and as of
the date of the Closing.

 

5.2 Performance.
The Company shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that
are required to be performed or complied with by it on or before the Closing and shall have obtained all approvals, consents and
qualifications necessary to complete the purchase and sale described herein.

 

5.3 Securities
Exemptions. The offer and sale of the Purchased Shares to the Investors pursuant to this Agreement shall be exempt from
the registration requirements of the 1933 Act, the qualification requirements of the Law and the registration and/or qualification
requirements of all other applicable state securities laws.

 

6. CONDITIONS
TO THE COMPANY’S OBLIGATIONS AT CLOSING.

 

The
obligations of the Company to each Investor under this Agreement are subject to the fulfillment or waiver on or before the Closing
of each of the following conditions by such Investor:

 

6.1 Representations
and Warranties. The representations and warranties of such Investor contained in Section 4 shall be true and correct on
the date of the Closings with the same effect as though such representations and warranties had been made on and as of the Closings.

 

6.2 Payment
of Purchase Price. Each Investor shall have delivered to the Company the purchase price in accordance with the provisions
of Section 2.

 

6.3 Securities
Exemptions. The offer and sale of the Purchased Shares to the Investors pursuant to this Agreement shall be exempt from
the registration requirements of the 1933 Act, the qualifications requirements of the Law and the registration and/or qualification
requirements of all other applicable state securities laws.

 

    	 

     

    

 

6.4 Proceedings
and Documents. All corporate and other proceedings in connection with the transactions contemplated at the Closings and
all documents incident thereto shall be reasonably satisfactory in form and substance to the Company and to the Company’s
legal counsel, and the Company shall have received all such counterpart originals and certified or other copies of such documents
as it may reasonably request.

 

7. GENERAL
PROVISIONS.

 

7.1 Survival
of Warranties. The representations, warranties and covenants of the Company and the Investors contained in or made pursuant
to this Agreement shall survive the execution and delivery of this Agreement and the Closings and shall in no way be affected
by any investigation of the subject matter thereof made by or on behalf of any of the Investors, their counsel or the Company,
as the case may be.

 

7.2 Successors
and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective
successors and assigns of the parties.

 

7.3 Governing
Law. This Agreement shall be governed by and construed under the internal laws of the State of California as applied to
agreements among California residents entered into and to be performed entirely within California, without reference to principles
of conflict of laws or choice of laws.

 

7.4 Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

7.5 Headings.
The headings and captions used in this Agreement are used for convenience only and are not to be considered in construing or interpreting
this Agreement. All references in this Agreement to sections, paragraphs, exhibits and schedules shall, unless otherwise provided,
refer to sections and paragraphs hereof and exhibits and schedules attached hereto, all of which exhibits and schedules are incorporated
herein by this reference.

 

Notices.
Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed
effectively given upon personal delivery to the party to be notified or upon deposit with the United States Post Office, by registered
or certified mail, postage prepaid and addressed to the party to be notified at the address indicated for such party on the signature
page hereof, or, in the case of the Company, at 15638 Boulder Mountain Road, Poway California 92064; Attn: President with a copy
to Michael J. Kinkelaar, Esq., Procopio, Cory, Hargreaves & Savitch LLP, 525 B Street, Suite 2200, San Diego, California 92101
or at such other address as any party or the Company may designate by giving ten (10) days advance written notice to all other
parties.

 

7.6 No
Finder’s Fees. Each party represents that it neither is nor will be obligated for any finder’s or broker’s
fee or commission in connection with this transaction. Each Investor agrees to indemnify and to hold harmless the Company from
any liability for any commission or compensation in the nature of a finders’ or broker’s fee (and any asserted liability)
for which the Investor or any of its officers, partners, employees, or representatives is responsible.

 

    	 

     

    

 

7.7 Amendments
and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the
Company and the Investor. Any amendment or waiver effected in accordance with this Section shall be binding upon each holder of
any Purchased Shares at the time outstanding, each future holder of such securities, and the Company; provided, however, that
no condition set forth in Section 5 may be waived with respect to any Investor who does not consent thereto.

 

7.8 Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision(s) shall be excluded
from this Agreement and the balance of the Agreement shall be interpreted as if such provision(s) were so excluded and shall be
enforceable in accordance with its terms.

 

7.9 Entire
Agreement. This Agreement, together with all exhibits and schedules hereto, constitutes the entire agreement and understanding
of the parties with respect to the subject matter hereof and supersedes any and all prior negotiations, correspondence, agreements,
understandings duties or obligations between the parties with respect to the subject matter hereof.

 

7.10 Further
Assurances. From and after the date of this Agreement, upon the request of any Investor or the Company, the Company and
the Investors shall execute and deliver such instruments, documents or other writings as may be reasonably necessary or desirable
to confirm and carry out and to effectuate fully the intent and purposes of this Agreement.

 

In
Witness Whereof, the parties hereto have executed this Agreement as of the date first above written.

 

AEGEA
BIOTECHNOLOGIES, INC.

 

	By:	 	 
	 	Lyle
    J. Arnold, Jr, President	 

 

	INVESTOR:	Amount	Shares
	 	 	 
	Tauriga
    Sciences, Inc.	$	 

 

	By:	 	 
	 	Seth
    Shaw, CEO	 

 

Address
for Notice:

 

____________________________

____________________________

 

    	 

     

    

 

EXHIBIT
A

 

CERTIFICATE
OF INCORPORATION

OF
AEGEA BIOTECHNOLOGIES, INC.

 

[see
attached]

 

    	 

     

    

 

EXHIBIT
B

 

Bylaws

 

[see
attached]

 

    	 

     

    

 

EXHIBIT
C

 

Stock
Purchase Schedule

 

	Date
    of Purchase	 	Purchase
    Price	 	Number
    of Shares PurchasedExhibit 4.64

 

Note:
June 24, 2020

 

NEITHER
THESE SECURITIES NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES
AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT.

 

THIS
NOTE DOES NOT REQUIRE PHYSICAL SURRENDER OF THE NOTE IN THE EVENT OF A PARTIAL REDEMPTION OR CONVERSION. AS A RESULT, FOLLOWING
ANY REDEMPTION OR CONVERSION OF ANY PORTION OF THIS NOTE, THE OUTSTANDING PRINCIPAL SUM REPRESENTED BY THIS NOTE MAY BE LESS THAN
THE PRINCIPAL SUM AND ACCRUED INTEREST SET FORTH BELOW.

 

8%
FIXED CONVERTIBLE PROMISSORY NOTE

 

OF

 

TAURIGA
SCIENCES, INC.

 

Issuance
Date: June 24, 2020 Principal Sum: $210,000

 

THIS
NOTE is a duly authorized Fixed Convertible Promissory Note of Tauriga Sciences, Inc., a corporation duly organized and existing
under the laws of the State of Florida (the “Company”), designated as the Company’s 8% Fixed Convertible
Promissory Note due December 24, 2020 (“Maturity Date”) in the face amount of $210,000 (the “Note”).

 

FOR
VALUE RECEIVED, the Company hereby promises to pay to the order of Tangiers Global, LLC or its registered assigns or
successors-in-interest (the “Holder”) the Principal Sum of $210,000 (the “Principal
Sum”) and to pay “guaranteed” interest on the principal balance hereof at an amount equivalent to 8% of
the Principal Sum, to the extent such Principal Sum and “guaranteed” interest and any other interest, fees,
liquidated damages and/or items due to Holder herein have not been repaid or converted into the Company’s Common Stock
(the “Common Stock”), in accordance with the terms hereof. The sum of $200,000 shall be remitted and
delivered to the Company, and $10,000 shall be retained by the Holder through an original issue discount (the
“OID”) for due diligence and legal bills related to this transaction. The OID is set at 5% of any
consideration paid. The Company covenants that within 2 months of the Effective Date of the Note, it shall utilize
approximately $200,000 of the proceeds in the manner set forth on Schedule 1, attached hereto (the “Use of
Proceeds”), and shall promptly provide evidence thereof to Holder, in sufficient detail as reasonably requested by
Holder.

 

    	1

     

    

 

In
addition to the “guaranteed” interest referenced above, and in the Event of Default pursuant to Section 3.00(a), additional
interest will accrue from the date of the Event of Default at the rate equal to the lower of 18% per annum or the highest rate
permitted by law (the “Default Rate”).

 

This
Note will become effective only upon the execution by both parties, including the execution of Exhibits B, C, D, E, Schedule 1
(collectively, the “Exhibits”), and the Irrevocable Transfer Agent Instructions (the “Date of Execution”)
and delivery of the initial payment of consideration by the Holder (the “Effective Date”). The Company acknowledges
and agrees the Exhibits are material provisions of this Note.

 

As
an investment incentive, the Company shall issue to the Holder 500,000 shares of its Common Stock (the “Origination Shares”),
which shares shall be issued and delivered to the Holder within 3 Trading Days of the Date of Execution.

 

For
purposes hereof the following terms shall have the meanings ascribed to them below:

 

“Business
Day” shall mean any day other than a Saturday, Sunday or a day on which commercial banks in the City of New York
are authorized or required by law or executive order to remain closed.

 

“Fixed
Conversion Price” shall be fixed at a price per share equal to $.03.

 

“Principal
Amount” shall refer to the sum of (i) the original principal amount of this Note (including the original issue
discount, prorated if the Note has not been funded in full), (ii) all guaranteed and other accrued but unpaid interest
hereunder, (iii) any fees due hereunder, (iv) liquidated damages, and (v) any default payments owing under the Note, in each
case previously paid or added to the Principal Amount.

 

“Principal
Market” shall refer to the primary exchange on which the Company’s common stock is traded or quoted.

 

“Trading
Day” shall mean a day on which there is trading or quoting for any security on the Principal Market.

 

“Underlying
Shares” means the shares of common stock into which the Note is convertible (including interest, fees, liquidated
damages and/or principal payments in common stock as set forth herein) in accordance with the terms hereof.

 

The
following terms and conditions shall apply to this Note:

 

Section
1.00 Repayment.

 

(a)
The Company may pay this Note, in whole or in part, in cash or in other good funds, according to the following schedule:

 

	Days
    Since Effective Date	 	Payment
    Amount
	Under
    90	 	110%
    of Principal Amount so paid
	91-180	 	120%
    of Principal Amount so paid

 

    	2

     

    

 

(b)
After 180 days from the Effective Date, the Company may not pay this Note, in whole or in part, in cash or in other good funds,
without prior written consent from Holder, which consent may be withheld, delayed, denied, or conditioned in Holder’s sole
and absolute discretion. Whenever any amount expressed to be due by the terms of this Note is due on any day that is not a Business
Day, the same shall instead be due on the next succeeding day that is a Business Day. Upon the occurrence of an Event of Default,
the Company may not pay the Note, in whole or in part, in cash or in other good funds without written consent of the Holder, which
consent may be withheld, delayed, denied, or conditioned in Holder’s sole and absolute discretion. Further, the Company
shall provide the Holder with two weeks’ prior written notice of the Company’s determination to pay any or all of
its obligations hereunder. During such two-week period, the Holder may exercise any or all of its conversion rights hereunder.
In the event that the Holder does not exercise its conversion rights in respect of any or all of such noticed, prospective payment,
the Company shall tender the full amount set forth in such notice (less any amount in respect of which the Holder has exercised
its conversion rights) to the Holder within 2 Business Days following the Holder’s exercise (or notification to the Company
of non-exercise) of the Holder’s conversion rights in respect of the amount set forth in such notice. Any such payment by
the Company in connection with this provision shall be deemed to have been made on the date that the Holder first receives the
above-referenced notice.

 

Section
2.00 Conversion.

 

(a)
Conversion Right. Subject to the terms hereof and restrictions and limitations contained herein, the Holder shall have
the right, at the Holder’s sole option, at any time and from time to time to convert in whole or in part the outstanding
and unpaid Principal Amount under this Note into shares of Common Stock as per the Conversion Price, but not to exceed the Restricted
Ownership Percentage, as defined in Section 2.00(f). The date of any conversion notice (“Conversion Notice”)
hereunder shall be referred to herein as the “Conversion Date”.

 

(b)
Stock Certificates or DWAC. The Company will deliver to the Holder, or Holder’s authorized designee, no later than
2 Trading Days after the Conversion Date, a certificate or certificates (which certificate(s) shall be free of restrictive legends
and trading restrictions if the shares of Common Stock underlying the portion of the Note being converted are eligible under a
resale exemption pursuant to Rule 144(b)(1)(ii) and Rule 144(d)(1)(ii) of the Securities Act of 1933, as amended) representing
the number of shares of Common Stock being acquired upon the conversion of this Note. In lieu of delivering physical certificates
representing the shares of Common Stock issuable upon conversion of this Note, provided the Company’s transfer agent is
participating in Depository Trust Company’s (“DTC”) Fast Automated Securities Transfer (“FAST”)
program, the Company shall instead use commercially reasonable efforts to cause its transfer agent to electronically transmit
such shares issuable upon conversion to the Holder (or its designee), by crediting the account of the Holder’s (or such
designee’s) broker with DTC through its Deposits and Withdrawal at Custodian (“DWAC”) program (provided
that the same time periods herein as for stock certificates shall apply).

 

    	3

     

    

 

(c)
Charges and Expenses. Issuance of Common Stock to Holder, or any of its assignees, upon the conversion of this Note shall
be made without charge to the Holder for any issuance fee, transfer tax, legal opinion and related charges, postage/mailing charge
or any other expense with respect to the issuance of such Common Stock. Company shall pay all transfer agent fees incurred from
the issuance of the Common Stock to Holder, as well as any and all other fees and charges required by the transfer agent as a
condition to effectuate such issuance. Any such fees or charges, as noted in this Section that are paid by the Holder (whether
from the Company’s delays, outright refusal to pay, or otherwise), will be automatically added to the Principal Sum of the
Note and tack back to the Effective Date for purposes of Rule 144.

 

(d)
Delivery Timeline. If the Company fails to deliver to the Holder such certificate or certificates (or shares through the
DWAC program) pursuant to this Section (free of any restrictions on transfer or legends, if eligible) prior to 3 Trading Days
after the Conversion Date, the Company shall pay to the Holder as liquidated damages an amount equal to $2,000 per day, until
such certificate or certificates are delivered. The Company acknowledges that it would be extremely difficult or impracticable
to determine the Holder’s actual damages and costs resulting from a failure to deliver the Common Stock and the inclusion
herein of any such additional amounts are the agreed upon liquidated damages representing a reasonable estimate of those damages
and costs. Such liquidated damages will be automatically added to the Principal Sum of the Note and tack back to the Effective
Date for purposes of Rule 144.

 

(e)
Reservation of Underlying Securities. The Company covenants that it will at all times reserve and keep available for Holder,
out of its authorized and unissued Common Stock solely for the purpose of issuance upon conversion of this Note, free from preemptive
rights or any other actual contingent purchase rights of persons other than the Holder, three times the number of shares
of Common Stock as shall be issuable (taking into account the adjustments under this Section 2.00, but without regard to any ownership
limitations contained herein) upon the conversion of this Note (consisting of the Principal Amount), under the formula in Section
3.00(c) below, to Common Stock (the “Required Reserve”). The Company covenants that all shares of Common Stock
that shall be issuable will, upon issue, be duly authorized, validly issued, fully-paid, non-assessable and freely-tradable (if
eligible). If the amount of shares on reserve in Holder’s name at the Company’s transfer agent for this Note shall
drop below the Required Reserve, the Company will, within 2 Trading Days of notification from Holder, instruct the transfer agent
to increase the number of shares so that the Required Reserve is met. In the event that the Company does not instruct the transfer
agent to increase the number of shares so that the Required Reserve is met, the Holder will be allowed, if applicable, to provide
this instruction as per the terms of the Irrevocable Transfer Agent Instructions attached to this Note. The Company agrees that
the maintenance of the Required Reserve is a material term of this Note and any breach of this Section 2.00(e) will result in
a default of the Note.

 

(f)
Conversion Limitation. The Holder will not submit a conversion to the Company that would result in the Holder beneficially
owning more than 9.99% of the then total outstanding shares of the Company (“Restricted Ownership Percentage”).

 

(g)
Conversion Delays. If the Company fails to deliver shares in accordance with the timeframe stated in Section 2.00(d), the
Holder, at any time prior to selling all of those shares, may rescind any portion, in whole or in part, of that particular conversion
attributable to the unsold shares. The rescinded conversion amount will be returned to the Principal Sum with the rescinded conversion
shares returned to the Company, under the expectation that any returned conversion amounts will tack back to the Effective Date.

 

    	4

     

    

 

(h)
Shorting and Hedging. Holder may not engage in any “shorting” or “hedging” transaction(s) in the
Common Stock of the Company prior to conversion.

 

(i)
Conversion Right Unconditional. If the Holder shall provide a Conversion Notice as provided herein, the Company’s
obligations to deliver Common Stock shall be absolute and unconditional, irrespective of any claim of setoff, counterclaim, recoupment,
or alleged breach by the Holder of any obligation to the Company.

 

Section
3.00 Defaults and Remedies.

 

(a)
Events of Default. An “Event of Default” is: (i) a default in payment of any amount due hereunder; (ii)
a default in the timely issuance of underlying shares upon and in accordance with terms of Section 2.00, which default continues
for 2 Trading Days after the Company has failed to issue shares or deliver stock certificates within the 3rd Trading Day following
the Conversion Date; (iii) if the Company does not issue the press release or file the Current Report on Form 8-K, in each case
in accordance with the provisions and the deadlines referenced Section 5.00(i); (iv) failure by the Company for 3 days after notice
has been received by the Company to comply with any material provision of this Note; (v) any representation or warranty of the
Company in this Note that is found to have been incorrect in any material respect when made, including, without limitation, the
Exhibits; (vi) failure of the Company to remain compliant with DTC, thus incurring a “chilled” status with DTC; (vii)
any default of any mortgage, indenture or instrument which may be issued, or by which there may be secured or evidenced any indebtedness,
for money borrowed by the Company or for money borrowed the repayment of which is guaranteed by the Company, whether such indebtedness
or guarantee now exists or shall be created hereafter; (viii) if the Company is subject to any Bankruptcy Event; (ix) any failure
of the Company to satisfy its “filing” obligations under Securities Exchange Act of 1934, as amended (the “1934
Act”) and the rules and guidelines issued by OTC Markets News Service, OTCMarkets.com and their affiliates; (x) failure
of the Company to remain in good standing under the laws of its state of domicile; (xi) any failure of the Company to provide
the Holder with information related to its corporate structure including, but not limited to, the number of authorized and outstanding
shares, public float, etc. within 1 Trading Day of request by Holder; (xii) failure by the Company to maintain the Required Reserve
in accordance with the terms of Section 2.00(3); (xiii) failure of Company’s Common Stock to maintain a closing bid price
in its Principal Market for more than 3 consecutive Trading Days; (xiv) any delisting from a Principal Market for any reason;
(xv) failure by Company to pay any of its transfer agent fees in excess of $2,000 or to maintain a transfer agent of record; (xvi)
failure by Company to notify Holder of a change in transfer agent within 24 hours of such change; (xvii) any trading suspension
imposed by the United States Securities and Exchange Commission (the “SEC”) under Sections 12(j) or 12(k) of
the 1934 Act; (xviii) failure by the Company to meet all requirements necessary to satisfy the availability of Rule 144 to the
Holder or its assigns, including but not limited to the timely fulfillment of its filing requirements as a fully-reporting issuer
registered with the SEC, requirements for XBRL filings, and requirements for disclosure of financial statements on its website;
(xix) failure of the Company to abide by the Use of Proceeds or failure of the Company to inform the Holder of a change in the
Use of Proceeds; or (xx) failure of the Company to abide by the terms of the right of first refusal contained in Section 5.00(k).

 

    	5

     

    

 

(b)
Remedies. If an Event of Default occurs, the outstanding Principal Amount of this Note owing in respect thereof through
the date of acceleration, shall become, at the Holder’s election, immediately due and payable in cash at the “Mandatory
Default Amount”. The Mandatory Default Amount means 20% of the outstanding Principal Amount of this Note will be automatically
added to the Principal Sum of the Note and tack back to the Effective Date for purposes of Rule 144. Commencing 5 days after the
occurrence of any Event of Default that results in the eventual acceleration of this Note, this Note shall accrue additional interest,
in addition to the Note’s “guaranteed” interest, at a rate equal to the lesser of 18% per annum or the maximum
rate permitted under applicable law. In connection with such acceleration described herein, the Holder need not provide, and the
Issuer hereby waives, any presentment, demand, protest or other notice of any kind, and the Holder may immediately and without
expiration of any grace period enforce any and all of its rights and remedies hereunder and all other remedies available to it
under applicable law. Such acceleration may be rescinded and annulled by the Holder at any time prior to payment hereunder and
the Holder shall have all rights as a holder of the note until such time, if any, as the Holder receives full payment pursuant
to this Section 3.00(b). No such rescission or annulment shall affect any subsequent event of default or impair any right consequent
thereon. Nothing herein shall limit the Holder’s right to pursue any other remedies available to it at law or in equity
including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Issuer’s failure
to timely deliver certificates representing shares of Common Stock upon conversion of the Note as required pursuant to the terms
hereof.

 

(c)
Variable Conversion Price. If the Note is not retired on or before the Maturity Date, then at any time and from time to
time after the Maturity Date, and subject to the terms hereof and restrictions and limitations contained herein, the Holder shall
have the right, at the Holder’s sole option, to convert in whole or in part the outstanding and unpaid Principal Amount
under this Note into shares of Common Stock at the Variable Conversion Price. The “Variable Conversion Price”
(together with the Fixed Conversion Price, the “Conversion Price”) shall be equal to the lower of: (a)
the Fixed Conversion Price or (b) 70% of the lowest volume weight average price of the Company’s Common Stock during the
15 consecutive Trading Days prior to the date on which Holder elects to convert all or part of the Note. For the purpose of calculating
the Variable Conversion Price only, any time after 4:00 pm Eastern Time (the closing time of the Principal Market) shall be considered
to be the beginning of the next Business Day. If the Company is placed on “chilled” status with the DTC, the discount
shall be increased by 10%, i.e., from 30% to 40%, until such chill is remedied. If the Company is not DWAC eligible
through their transfer agent and DTC’s FAST system, the discount will be increased by 5%, i.e., from 30% to
35%. In the case of both, the discount shall be a cumulative increase of 15%, i.e., from 30% to 45%.

 

Section
4.00 Representations and Warranties of Holder.

 

Holder
hereby represents and warrants to the Company that:

 

(a)
Holder is an “accredited investor,” as such term is defined in Regulation D of the Securities Act of 1933, as amended
(the “1933 Act”), and will acquire this Note and the Underlying Shares (collectively, the “Securities”)
for its own account and not with a view to a sale or distribution thereof as that term is used in Section 2(a)(11) of the 1933
Act, in a manner which would require registration under the 1933 Act or any state securities laws. Holder has such knowledge and
experience in financial and business matters that such Holder is capable of evaluating the merits and risks of the Securities.
Holder can bear the economic risk of the Securities, has knowledge and experience in financial business matters and is capable
of bearing and managing the risk of investment in the Securities. Holder recognizes that the Securities have not been registered
under the 1933 Act, nor under the securities laws of any state and, therefore, cannot be resold unless the resale of the Securities
is registered under the 1933 Act or unless an exemption from registration is available. Holder has carefully considered and has,
to the extent Holder believes such discussion necessary, discussed with its professional, legal, tax and financial advisors, the
suitability of an investment in the Securities for its particular tax and financial situation and its advisers, if such advisors
were deemed necessary, and has determined that the Securities are a suitable investment for it. Holder has not been offered the
Securities by any form of general solicitation or advertising, including, but not limited to, advertisements, articles, notices
or other communications published in any newspaper, magazine, or other similar media or television or radio broadcast or any seminar
or meeting where, to Holders’ knowledge, those individuals that have attended have been invited by any such or similar means
of general solicitation or advertising. Holder has had an opportunity to ask questions of and receive satisfactory answers from
the Company, or any person or persons acting on behalf of the Company, concerning the terms and conditions of the Securities and
the Company, and all such questions have been answered to the full satisfaction of Holder. The Company has not supplied Holder
any information regarding the Securities or an investment in the Securities other than as contained in this Agreement, and Holder
is relying on its own investigation and evaluation of the Company and the Securities and not on any other information.

 

    	6

     

    

 

(b)
The Holder is a limited liability company duly organized, validly existing and in good standing under the laws of the state of
its incorporation and has all requisite corporate power and authority to carry on its business as now conducted. The Holder is
duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have
a material adverse effect on its business or properties.

 

(c)
All limited liability company action has been taken on the part of the Holder, its officers, directors, managers and members necessary
for the authorization, execution and delivery of this Note. The Holder has taken all limited liability company action required
to make all of the obligations of the Holder reflected in the provisions of this Note, valid and enforceable obligations.

 

(d)
Each certificate or instrument representing Securities will be endorsed with the following legend (or a substantially similar
legend), unless or until registered under the 1933 Act or exempt from registration:

 

THE
SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE
SOLD, TRANSFERRED, ASSIGNED OR HYPOTHECATED UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT COVERING SUCH SECURITIES,
THE TRANSFER IS MADE IN COMPLIANCE WITH RULE 144 PROMULGATED UNDER SUCH ACT OR THE COMPANY RECEIVES AN OPINION OF COUNSEL FOR
THE HOLDER OF THESE SECURITIES WHICH IS REASONABLY SATISFACTORY TO THE COMPANY, STATING THAT SUCH SALE, TRANSFER, ASSIGNMENT OR
HYPOTHECATION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SUCH ACT.

 

    	7

     

    

 

Section
5.00 General.

 

 (a) Payment of Expenses. The Company agrees to pay all reasonable charges and expenses, including attorneys’ fees and expenses, which may be incurred by the Holder in successfully enforcing this Note and/or collecting any amount due under this Note.

 

(b)
Assignment, Etc. The Holder may assign or transfer this Note to any transferee at its sole discretion. This Note shall
be binding upon the Company and its successors and shall inure to the benefit of the Holder and its successors and permitted assigns.

 

(c)
Amendments. This Note may not be modified or amended, or any of the provisions of this Note waived, except by written agreement
of the Company and the Holder.

 

(d)
Funding Window. The Company agrees that it will not enter into a convertible debt financing transaction, including 3(a)9
and 3(a)10 transactions, with any party other than the Holder for a period of 45 Trading Days following the Effective Date and
each Additional Tranche Date, as relevant. The Company agrees that this is a material term of this Note and any breach of this
Section 5.00(d) will result in a default of the Note.

 

(e)
Terms of Future Financings. So long as this Note is outstanding, upon any issuance by the Company or any of its subsidiaries
of any convertible debt security (whether such debt begins with a convertible feature or such feature is added at a later date)
with any term more favorable to the holder of such security or with a term in favor of the holder of such security that was not
similarly provided to the Holder in this Note, then the Company shall notify the Holder of such additional or more favorable term
and such term, at the Holder’s option, shall become a part of this Note and its supporting documentation.. The types of terms
contained in the other security that may be more favorable to the holder of such security include, but are not limited to, terms
addressing conversion discounts, terms addressing maturity, conversion look back periods, interest rates, original issue discount
percentages and warrant coverage.

 

(f)
Governing Law; Jurisdiction.

 

(i)
Governing Law. This Note will be governed by, and construed and interpreted in accordance with, the laws of the state of California
without regard to any conflicts of laws or provisions thereof that would otherwise require the application of the law of any other
jurisdiction.

 

(ii)
Jurisdiction and Venue. Any dispute, claim, suit, action or other legal proceeding arising out of or relating to this Note
or the rights and obligations of each of the parties shall be brought only in the state courts of California or in the federal
courts of the United States of America located in San Diego County, California.

 

(iii)
No Jury Trial. The Company hereto knowingly and voluntarily waives any and all rights it may have to a trial by jury with
respect to any litigation based on, or arising out of, under, or in connection with, this Note.

 

(iv)
Delivery of Process by the Holder to the Company. In the event of an action or proceeding by the Holder against the Company,
and only by the Holder against the Company, service of copies of summons and/or complaint and/or any other process that may be
served in any such action or proceeding may be made by the Holder via U.S. Mail, overnight delivery service such as FedEx or UPS,
email, fax, or process server, or by mailing or otherwise delivering a copy of such process to the Company at its last known attorney
as set forth in its most recent SEC filing.

 

    	8

     

    

 

(v)
Notices. Any notice required or permitted hereunder (including Conversion Notices) must be in writing and either personally
served, sent by facsimile or email transmission, or sent by overnight courier. Notices will be deemed effectively delivered at
the time of transmission if by facsimile or email, and if by overnight courier the business day after such notice is deposited
with the courier service for delivery.

 

(g)
No Bad Actor. No officer or director of the Company would be disqualified under Rule 506(d) of the Securities Act of 1933,
as amended, on the basis of being a “bad actor” as that term is established in the September 13, 2013 Small Entity
Compliance Guide published by the SEC.

 

(h)
Usury. If it shall be found that any interest or other amount deemed interest due hereunder violates any applicable law
governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate of interest
permitted under applicable law. The Company covenants (to the extent that it may lawfully do so) that it will not seek to claim
or take advantage of any law that would prohibit or forgive the Company from paying all or a portion of the principal, fees, liquidated
damages or interest on this Note.

 

(i) Securities
Laws Disclosure; Publicity. The Company shall (a) by 9:30 a.m. Eastern Time on the Trading Day immediately following the
Date of Execution, issue a press release disclosing the material terms of the transactions contemplated hereby, and (b) file
a Current Report on Form 8-K with the SEC within the time required by the 1934 Act. From and after the filing of such press
release the Company represents to the Holder that it shall have publicly disclosed all material, non-public information
delivered to the Holder by the Company, or any of its officers, directors, employees, or agents in connection with the
transactions contemplated by this Note. The Company and the Holder shall consult with each other in issuing any other press
releases with respect to the transactions contemplated hereby, and neither the Company nor the Holder shall issue any such
press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any
press release of the Holder, or without the prior consent of the Holder, with respect to any press release of the Company,
none of which consents shall be unreasonably withheld, delayed, denied, or conditioned except if such disclosure is required
by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement
or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of the Holder, or include
the name of the Holder in any filing with the SEC or any regulatory agency or Principal Market, without the prior written
consent of the Holder, except to the extent such disclosure is required by law or Principal Market regulations, in which case
the Company shall provide the Holder with prior notice of such disclosure permitted hereunder.

 

The
Company agrees that this is a material term of this Note and any breach of this Section 5.00(i) will result in a default of the
Note.

 

    	9

     

    

 

(j)
Attempted Below-par Issuance. In the event that (i) any requested conversion hereunder shall be at a Conversion Price that
is less than then-current par value of the Company’s Common Stock and that any or all of such requested conversion would
be precluded by state law or otherwise and (ii) within three business days of the requested conversion, the Company shall not
have reduced its par value such that all of the requested conversion may then be accomplished, then the Company and the Holder
agree to the following conversion protocol: the Holder shall generate and transmit to the Company (X) a “preliminary”
Conversion Notice for the full number of shares of Common Stock of the above-referenced conversion at the Conversion Price without
regard to any below-par value conversion issues; (Y) a “par value” Conversion Notice for the number of shares of Common
Stock for the above-referenced conversion with the Conversion Price increased from the Conversion Price set forth in the “preliminary”
Conversion Notice to a Conversion Price at par value; and (Z) a “liquidated damages” Conversion Notice for that number
of shares of Common Stock that represents the difference between the number of shares of Common Stock in the “preliminary”
Conversion Notice and the number of shares of Common Stock in the “par value” Conversion Notice and the Conversion
Price of such “liquidated damages Common Shares” would be the par value of the Common Stock. The Company acknowledges
that any failure by it to provide the Holder with its full conversion rights under this Note (as a result of a proposed “below
par” conversion) will cause the Holder to incur substantial economic damages and losses of types and in amounts that are
impossible to compute and ascertain with certainty as a basis for recovery by the Holder of actual damages and that liquidated
damages would represent a fair, reasonable, and appropriate estimate thereof. Accordingly, in the event that the Holder is precluded
from exercising any or all of its conversion rights hereunder as a result of a proposed “below par” conversion, the
Company agrees that, in lieu of actual damages for such failure, liquidated damages may be assessed and recovered by the Holder
without being required to present any evidence of the amount or character of actual damages sustained by reason thereof. The amount
of such liquidated damages shall be an amount equivalent to the trading price (without discount) utilized in the “preliminary”
Conversion Notice multiplied by the number of shares calculated on the “liquidated damages” Conversion Notice. Such
amount shall be assessed and become immediately due and payable to the Holder (at its election) in the form of a cash payment,
an addition to the Principal Sum of this Note, or the immediate issuance of that number of shares of Common Stock as calculated
on the “liquidated damages” Conversion Notice. Such liquidated damages are intended to represent estimated actual
damages and are not intended to be a penalty, but, by virtue of their genesis and subject to the election of the Holder (as set
forth in the immediately preceding sentence), will be automatically added to the Principal Sum of the Note and tack back to the
Effective Date for purposes of Rule 144.

 

(k)
Right of First Refusal. From and after the date of this Note and at all times hereafter while the Note is outstanding,
the Parties agree that, in the event that the Company receives any written or oral proposal (the “Proposal”)
containing one or more offers to provide additional capital or equity or debt financing (the “Financing Amount”),
the Company agrees that it shall provide a copy of all documents received relating to the Proposal together with a complete and
accurate description of the Proposal to the Holder and all amendments, revisions, and supplements thereto (the “Proposal
Documents”) no later than 3 business days from the receipt of the Proposal Documents. Following receipt of the Proposal
Documents from the Company, the Holder shall have the right (the “Right of First Refusal”), but not the obligation,
for a period of 5 business days thereafter (the “Exercise Period”), to invest, at similar or better terms to
the Company, an amount equal to or greater than the Financing Amount, upon written notice to the Company that the Holder is exercising
the Right of First Refusal provided hereby. In furtherance of the Right of First Refusal, the Company agrees that it will cooperate
and assist the Holder in conducting a due diligence investigation of the Company and its corporate and financial affairs and promptly
provide the Holder with information and documents that the Holder may reasonably request so as to allow the Holder to make an
informed investment decision. However, the Company and the Holder agree that the Holder shall have no more than 5 business days
from and after the expiration of the Exercise Period to exercise its Right of First Refusal hereunder. This Right of First Refusal
shall extend to all purchases of debt held by, or assigned to or from, current stockholders, vendors, or creditors, all transactions
under Sections 3(a)(9) and/or 3(a)(10) or the Securities Act of 1933, as amended, and all equity line-of-credit transactions.
In the event that the Company does enter into, or makes any issuance of Common Stock related to a 3(a)(9) Transaction or a 3(a)(10)
Transaction while this note is outstanding, without giving Right of First Refusal to the Holder, a liquidated damages charge of
25% of the outstanding principal balance of this Note, but not less than $25,000, will be assessed and will become immediately
due and payable to the Holder at its election in the form of cash payment or addition to the balance of this Note. Such liquidated
damages will be automatically added to the Principal Sum of the Note and tack back to the Effective Date for purposes of Rule
144.

 

[Signature
Page to Follow.]

 

    	10

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Fixed Convertible Promissory Note to be duly executed on the day and in the year
first above written.

 

	 	TAURIGA
    SCIENCES, INC.
	 	 	 
	 	By:	 
	 	Name:	Seth M. Shaw
	 	Title:
    	Chief
    Executive Officer 
	 	Email:	sshaw@tauriga.com
	 	Address:	555
    Madison Avenue / NY, NY 10022

 

This
Fixed Convertible Promissory Note of June 24, 2020 is accepted this __ day of __________, 2020 by

 

	TANGIERS
    GLOBAL, LLC	 
	 	 	 
	By:	 	
	Name:	 	 
	Title:	Managing
    Member	 

 

    	11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]